Adrian Adams - 14 Feb 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC

Reporting relationship: COB, CEO and President, Director
Issuer ticker: N/A
Reported as of: 14 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Feb 2023, 17:19:35 UTC
Prior SEC filing: 15 Jul 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ John Leaman, M.D. as attorney-in-fact

Key filing fact

Adrian Adams filed Form 4 for IMPEL PHARMACEUTICALS INC on 16 Feb 2023.

Key facts

This page summarizes Adrian Adams's Form 4 filing for IMPEL PHARMACEUTICALS INC.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Feb 2023, 17:19.

Change

Previous filing in this sequence was filed on 15 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMPL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 14 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $2.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.